Search Results - "Nowotny, Irene"

130-LB: Comparative PK and PD of the Rapid-Acting Insulin Aspart Product SAR341402, NovoLog, and NovoRapid in Subjects with T1D by KAPITZA, CHRISTOPH, NOSEK, LESZEK, LEHMANN, ANNE, SCHMIDER, WOLFGANG, ROTTHAEUSER, BAERBEL, NOWOTNY, IRENE K.

“…SAR341402 (SAR-Asp), NovoLog (NN-Asp-US) and NovoRapid (NN-Asp-EU) are rapid-acting insulin aspart products. Exposure (PK) to and activity (PD) of SAR-Asp (T)…”
Get full text

Pharmacokinetic and pharmacodynamic similarity between SAR341402 insulin aspart and Japan-approved NovoRapid in healthy Japanese subjects by Shiramoto, Masanari, Yoshihara, Tatsuya, Schmider, Wolfgang, Takagi, Hiroki, Nowotny, Irene, Kajiwara, Miyuki, Muto, Hideya

“…This study compared the pharmacokinetic and glucodynamic profiles of biosimilar SAR341402 insulin aspart to Japan-approved insulin aspart (NovoRapid) in…”
Get full text

137-LB: Safety Assessment of SAR341402 and NovoLog When Administered through an Insulin Pump by THRASHER, JAMES, POLSKY, SARIT, HOVSEPIAN, LIONEL, NOWOTNY, IRENE K., BOIS DE FER, BéATRICE, BHARGAVA, ANUJ, GARG, SATISH K.

“…SAR341402 (SAR-Asp) is a biosimilar/follow-on insulin to NovoLog® (NN-Asp). This non-confirmatory, randomized, open-label, 2x4 week, 2 arm crossover study in…”
Get full text

Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist by Bossart, Martin, Wagner, Michael, Elvert, Ralf, Evers, Andreas, Hübschle, Thomas, Kloeckener, Tim, Lorenz, Katrin, Moessinger, Christine, Eriksson, Olof, Velikyan, Irina, Pierrou, Stefan, Johansson, Lars, Dietert, Gabriele, Dietz-Baum, Yasmin, Kissner, Thomas, Nowotny, Irene, Einig, Christine, Jan, Christelle, Rharbaoui, Faiza, Gassenhuber, Johann, Prochnow, Hans-Peter, Agueusop, Inoncent, Porksen, Niels, Smith, William B., Nitsche, Almut, Konkar, Anish

“…Unimolecular triple incretins, combining the activity of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon…”
Get full text

Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes by Kapitza, Christoph, Nosek, Leszek, Schmider, Wolfgang, Teichert, Lenore, Nowotny, Irene

“…The objective of this study was to demonstrate the pharmacokinetic and pharmacodynamic similarity among SAR341402 insulin aspart biosimilar/follow-on product,…”
Get more information

A single‐dose euglycaemic clamp study in two cohorts to compare the exposure of SAR341402 (insulin aspart) Mix 70/30 with US‐ and European‐approved versions of insulin aspart Mix 70/30 and SAR341402 rapid‐acting solution in subjects with type 1 diabetes by Kapitza, Christoph, Nosek, Leszek, Schmider, Wolfgang, Teichert, Lenore, Mukherjee, Bhaswati, Nowotny, Irene

“…Aim To compare the pharmacokinetic exposure of SAR341402 Mix 70/30 (SARAsp‐Mix) with US‐ and European (EU)‐approved versions of insulin aspart Mix 70/30…”
Get full text

Similar pharmacokinetics and pharmacodynamics of rapid‐acting insulin lispro products SAR342434 and US‐ and EU‐approved Humalog in subjects with type 1 diabetes by Kapitza, Christoph, Nowotny, Irene, Lehmann, Anne, Bergmann, Karin, Rotthaeuser, Baerbel, Nosek, Leszek, Becker, Reinhard H. A.

“…Aim To compare the pharmacokinetics (PK) and pharmacodynamics (PD) of 3 rapid‐acting insulin lispro products: SAR342434 solution, United States (US)‐approved…”
Get full text

Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump by Thrasher, James, Surks, Howard, Nowotny, Irene, Pierre, Suzanne, Rotthaeuser, Baerbel, Wernicke-Panten, Karin, Garg, Satish

“…Background: SAR342434 (U100; SAR-Lis; insulin lispro) is a biosimilar/follow-on to insulin lispro (U100; Ly-Lis). Similar pharmacokinetics/pharmacodynamics…”
Get full text

Similar Pharmacokinetics and Pharmacodynamics of Biosimilar SAR342434 Insulin Lispro and Japan‐Approved Humalog Insulin Lispro in Healthy Japanese Subjects by Shiramoto, Masanari, Yoshihara, Tatsuya, Schmider, Wolfgang, Takahashi, Yoshinori, Nowotny, Irene, Kajiwara, Miyuki, Muto, Hideya

“…This phase 1 study compared the pharmacokinetic (PK) and glucose pharmacodynamic (PD) characteristics of biosimilar SAR342434 insulin lispro and…”
Get full text

Safety and Tolerability of Insulin Aspart Biosimilar SAR341402 Versus Originator Insulin Aspart (NovoLog) When Used in Insulin Pumps in Adults with Type 1 Diabetes: A Randomized, Open-Label Clinical Trial by Thrasher, James, Polsky, Sarit, Hovsepian, Lionel, Nowotny, Irene, Pierre, Suzanne, Bois De Fer, Béatrice, Bhargava, Anuj, Mukherjee, Bhaswati, Garg, Satish K

“…The aim was to assess the safety and tolerability of the insulin aspart biosimilar/follow-on product SAR341402 (100 U/mL solution; SAR-Asp) and originator…”
Get more information

Ease of Use of the Insulin Glargine 300 U/mL Pen Injector in Insulin-Naïve People With Type 2 Diabetes by Pohlmeier, Harald, Berard, Lori, Brulle-Wohlhueter, Claire, Wu, Junlong, Dahmen, Raphael, Nowotny, Irene, Klonoff, David

“…Background: Insulin glargine 300 U/mL (Gla-300) contains the same active ingredient as glargine 100 U/mL (Gla-100), and provides the same number of units in…”
Get full text

Low Within- and Between-Day Variability in Exposure to New Insulin Glargine 300 U/mL by Hramiak, Irene, Becker, Reinhard Ha, Nowotny, Irene, Teichert, Lenore, Bergmann, Karin, Kapitza, Christoph

Get full text